Ani Pharmaceuticals (ANIP) Retained Earnings: 2009-2025
Historic Retained Earnings for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to -$50.6 million.
- Ani Pharmaceuticals' Retained Earnings rose 43.54% to -$50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.6 million, marking a year-over-year increase of 43.54%. This contributed to the annual value of -$100.3 million for FY2024, which is 25.14% down from last year.
- Latest data reveals that Ani Pharmaceuticals reported Retained Earnings of -$50.6 million as of Q3 2025, which was up 34.18% from -$76.9 million recorded in Q2 2025.
- Ani Pharmaceuticals' 5-year Retained Earnings high stood at -$5.0 million for Q1 2021, and its period low was -$100.3 million during Q4 2024.
- Over the past 3 years, Ani Pharmaceuticals' median Retained Earnings value was -$80.9 million (recorded in 2023), while the average stood at -$79.8 million.
- In the last 5 years, Ani Pharmaceuticals' Retained Earnings surged by 56.95% in 2021 and then slumped by 1,257.31% in 2022.
- Quarterly analysis of 5 years shows Ani Pharmaceuticals' Retained Earnings stood at -$47.8 million in 2021, then crashed by 103.68% to -$97.3 million in 2022, then increased by 17.63% to -$80.1 million in 2023, then decreased by 25.14% to -$100.3 million in 2024, then skyrocketed by 43.54% to -$50.6 million in 2025.
- Its Retained Earnings was -$50.6 million in Q3 2025, compared to -$76.9 million in Q2 2025 and -$85.0 million in Q1 2025.